Effect of Combined Therapy on Colistin Resistant *Pseudomonas aeruginosa*: An *in Vitro* Study

Nuzhath Fatima1* , Amany Marwan1, Alkhansa Anwar1, Aymen Madhkhali2, Nahed Ali1, Areej Gadi1, Amany Hasnany1, Razan Hassan Hamali1, Mousa Ali Ayyashi3, Yahya Hobani2

1Department of Medical Laboratory Technology, College of Applied Medical Sciences, Jazan University, Jazan, KSA
2College of Applied Medical Sciences, Jazan University, Jazan, KSA
3Prince Mohammed Bin Nasser Hospital, Jazan, KSA

Email: *nfatima@jaznu.edu.sa

How to cite this paper: Fatima, N., Marwan, A., Anwar, A., Madhkhali, A., Ali, N., Gadi, A., Hasnany, A., Hamali, R.H., Ayyashi, M.A. and Hobani, Y. (2019) Effect of Combined Therapy on Colistin Resistant *Pseudomonas aeruginosa*: An *in Vitro* Study. Advances in Microbiology, 9, 877-892. https://doi.org/10.4236/aim.2019.910054

Received: September 16, 2019
Accepted: October 18, 2019
Published: October 21, 2019

Copyright © 2019 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

http://creativecommons.org/licenses/by/4.0/

Abstract

*Pseudomonas aeruginosa* is known for its antibiotic resistance to the clinicians. The infections caused by this pathogen are hard to treat because of its highly versatile property to mutate and acquire drug resistance. *Pseudomonas aeruginosa* also possesses intrinsic property of resistance to certain antibiotics like tetracyclines. However; in a practice to overcome the problem of multi drug resistance, clinicians restored the use of some antibiotics that were previously been used to treat the Pseudomonal infections; but they were discontinued because of its toxic effects. Colistin is an example of one such antibiotic. Use of Colistin was barred for its neurotoxicity. However in recent clinical trials, Colistin was reintroduced to fight with this superbug. Sadly in recent years, *Pseudomonas aeruginosa* developed resistance to Colistin as well. Therefore combined therapy is an alternate and suitable treatment to overcome the infections caused by multidrug-resistant *Pseudomonas aeruginosa*. The present study is an *in vitro* study, in which we tested synergy between two antibiotics namely streptomycin and Colistin on 29 clinical isolates of *P. aeruginosa* collected from hospitals in Jazan city KSA. The combination of two drugs showed synergistic activity on 55.1% of tested strains, while 20.6% strains had partial synergy, whereas indifferent synergy was observed in 13.8% strains and the 6.8% of strains had additive synergy. In addition to this, the drugs when combined also showed antagonism on one strain (3.44%). The present study showed synergistic action on Colistin-resistant *Pseudomonas aeruginosa* to greater extent (55.1%) by the two tested drugs. Hence Colistin and streptomycin can be used as a suitable combination therapy (*in vivo*) to treat multidrug resistant *P. aeruginosa* infections.
Keywords
“MDR”—Multidrug Resistant, “MIC”—Minimum Inhibitory Concentration, “FICI”—Fractional Inhibitory Concentration Index, “MHB”—Muller Hinton Broth, Pseudomonas aeruginosa

1. Introduction
Antibiotic resistance is one of the major concerns in treating the bacterial infections around the world; Pseudomonas aeruginosa is among the fast-developing antibiotic-resistant bacterial species; this bacterium is a gram-negative, opportunistic pathogen and a significant cause of acute and chronic infections in patients with compromised host defenses. Pseudomonas aeruginosa is a leading cause of nosocomial infections, such as infections of urinary tract, surgical sites wounds, bacteremia and middle ear infections etc. [1]. This organism is highly susceptible to mutations and is continuously exhibiting resistance to a number of antibiotics. Standard antibiotic regimes against P. aeruginosa are increasingly becoming ineffective due to the rise in drug resistance [2]. The treatment of the infections caused by this pathogen is getting difficult day by day because of the emergence of (MDR) multi drug resistance strains [3] [4]. P. aeruginosa is popular for its antibiotic resistance against drugs such as carbapenems, fluoroquinolones and aminoglycosides [3]. Mechanisms responsible for multidrug resistance include restricted permeability to drugs, changes in efflux systems; drug inactivation and changes in targets [5]. Apart from being resistant to antibiotics the sub-inhibitory concentrations of antibiotics such as tetracyclines can increase the cytotoxicity of this bacteria by four folds; in addition to this, sub-inhibitory concentrations of antibiotics namely tobramycin and ciprofloxacin induce biofilm formation in Pseudomonas aeruginosa [6]. Many countries have reported the rise of antibiotic-resistant strains of P. aeruginosa; Among Gulf co-operation council (GCC) countries, 92.3% clinical isolates of P. aeruginosa from Saudi Arabia were reported to be resistant to antibiotics [7]. In order to fight with multidrug-resistant Pseudomonal infections Colistin is the drug of choice. Many studies have communicated Colistin treatment being successful; in patients with nosocomial infections, pulmonary infections and in cancer patients suffering from MDR Pseudomonas aergonisina infections [8] [9] [10]. On the other hand resistance to Colistin has also been reported by many countries in clinical isolates of P. aeruginosa [11] [12]. However in situation of Colistin resistance, it requires some other alternative solution such as combined therapy to fight with the multidrug resistance strains of Pseudomonas aeruginosa. Combination therapies usually are effective in situation of antibiotic resistance. Studies have shown the synergistic action of Colistin with other drugs on MDR Pseudomonas aeruginosn [13] [14]. Therefore the present study is an attempt to deduce synergistic activity of Streptomycin and Colistin on Colistin resistant Pseu-
*Pseudomonas aeruginosa* under *in vitro* conditions and to determine the incidence of multi drug-resistant *Pseudomonas aeruginosa* in Jazan region of Saudi Arabia.

### 2. Materials & Methods

**Incidence of MDR *P. aeruginosa***: To discover the incidence of multidrug resistance pseudomonal infections in Jazan region. A total of 174 case reports on *Pseudomonas aeruginosa* were collected from microbiology lab of hospitals in Jazan city and their antibiotic sensitivity for four anti pseudomonal drugs such as Pipercillin, cefepime, ceftazidime and gentamycin were studied.

**Collection of *Pseudomonas aeruginosa* cultures**: Twenty nine clinical isolates of MDR *Pseudomonas aeruginosa* along with their identification & susceptibility reports were collected during year 2017-2018 from microbiology labs of hospitals in Jazan region, K.SA.

**Identification of *P. aeruginosa* (MDR) isolates in Microbiology lab (College of applied medical sciences)**: All the 29 clinical isolates, multi drug resistant (MDR) were re-identified by culturing on cetrimide agar to study pigmentation and colony morphology. Gram staining of the colonies was performed to study the morphology of isolates. Biochemical identification was done by performing oxidase test [15].

**Determination of Colistin resistance**: Colistin sensitivity test was performed by disc diffusion technique. The isolates and reference strain of *Pseudomonas aeruginosa* (control) was sub cultured on Muller hinton agar plates and from each 24 hrs subculture plates an inoculum of 0.5 Mcfarland unit turbid suspension was prepared respectively. A sterile swab was dipped into each suspension and was spread on sterile Muller hinton agar plates. After spreading the inoculum 10 µg Colistin disc was placed in the center of the plates. The plates were then incubated at 37˚C for 24 hrs. After incubation the plates were observed for zone of inhibition. The zone of inhibition was measured in millimeter (mm). The susceptibility or resistance interpretations were determined in accordance to National Committee for Clinical Laboratory Standards (NCCLS) standard breakpoints [16].

**Determination of MIC (minimum inhibitory concentration)**: All the 29 resistant cultures were tested by minimum inhibitory concentration technique. The protocol for MIC is preparation of two fold dilution of each drug (streptomycin alone and Colistin alone) and combination of two drugs (streptomycin-Colistin combined) which were prepared in Muller hinton broth tubes (macrobroth dilution technique). The concentrations ranging from 500 µg·ml⁻¹ - 15.6 µg·ml⁻¹ respectively was obtained [17].

**Inoculum preparation for MIC**: An inoculum adjusted to 0.5 McFarland turbidity was diluted to obtain a concentration of 5 × 10⁵ CFU/mL i.e. 2.0 ml of the 0.5 McFarland suspension is diluted into 38 ml sterile water (1:20 dilution). Then 0.01 ml of the diluted suspension is delivered to each tube with Muller hinton broth with concentrations of antibiotics ranging from 500 µg·ml⁻¹ - 15.6 µg·ml⁻¹ respectively. After inoculation the tubes were incubated at 37˚C for 18
hrs. Inoculums for reference strains from American type culture collection (ATCC) were also prepared and tested for MIC as positive controls while tubes, without any inoculum was considered as negative control. After incubation the tubes were observed for visual turbidity. The lowest concentration of antibiotic or combined that completely inhibits visual growth of bacteria (no turbidity) was recorded as MIC [16].

The synergistic effect of streptomycin and Colistin: The synergy of Colistin and streptomycin at different concentrations on Colistin resistant *Pseudomonas aeroginosa* was determined by *FICI* (fractional inhibitory concentration index). *FICI* is described as the sum of the MIC of each drug when used in combination divided by the MIC of the drug used alone.

The formula to calculate *FICI* is as follows:

\[
FICI = \left( \frac{\text{MIC drug A in combo}}{\text{MIC drug A alone}} \right) + \left( \frac{\text{MIC drug B in combo}}{\text{MIC drug B alone}} \right)
\]

The Synergistic effect will be recorded when *FICI* indexes is ≤ 0.5, partial Synergy, if value < 1.0; additive when *FICI* = 1.0; indifferent when *FICI* > 1.0 but < 4.0 and antagonistic when *FICI* ≥ 4.0 [18] [19].

3. Results

Incidence of MDR *P. aeruginosa* (2017-2018):

Upon analyzing the data collected, it was determined that out 173 clinical cases reported 96 isolates *i.e.* (55.5%) were multidrug-resistant *P. aeruginosa* strains and 77 (44.5%), isolates were found to be sensitive to routinely used anti Pseudomonal drugs as shown in Table 1. Figure 1.

**Colistin Resistance:** The Zone of inhibition diameters obtained following the Colistin susceptibility test it was found that all the 29 isolates tested were resistant to Colistin antibiotic. According to NCCLS breakpoints a *Pseudomonas aeruginosa* strain is sensitive to Colistin if the zone diameter is ≥10 mm. In our study on 29 isolates, the zone diameters obtained were <10 mm as shown in Table 2 & Figure 2.

**Synergistic activity:** Based on the *FICI* results obtained we found that the combination of Colistin and streptomycin showed synergistic killing of nineteen strains (55.1%) seven strains (20.6%) had partial synergistic action by the drugs. Similarly indifferent synergy was observed on five strains. Two strains showed additive synergy (6.8%) while two strains (3.4%) showed antagonism to the combined drugs as shown in Table 3.

4. Discussion

Treating multi drug resistance is the current major challenges for clinicians. It is reported that *Pseudomonas aeruginosa* is the most common non fermenting isolates in clinical samples in Saudi Arabia [20]. In the present study the incidence of *Pseudomonas aeruginosa* isolates causing infections were studied; it was found that 55.5% of the isolates were multi drug resistant; Among which
Table 1. Sensitivity pattern of *P. aeruginosa* against four anti-pseudomonal drugs such as Pipercillin, cefepime, Ceftazidime, Gentamicin.

| S. No. | Sample No. | Sample type     | Antibiotic susceptibility |
|-------|------------|-----------------|---------------------------|
|       |            |                 | Pipercillin | Cefepime | Ceftazidime | Gentamicin |
| 1     | 1          | Wound           | R          | R        | R          | R          |
| 2     | 2          | Wound           | S          | I        | I          | R          |
| 3     | 3          | Sputum          | R          | R        | R          | I          |
| 4     | 4          | Sputum          | R          | I        | R          | R          |
| 5     | 5          | Wound swab      | R          | R        | R          | I          |
| 6     | 6          | Blood           | I          | S        | S          | S          |
| 7     | 7          | Sputum          | I          | S        | S          | S          |
| 8     | 8          | Throat swab     | R          | R        | R          | S          |
| 9     | 9          | Throat          | R          | R        | R          | S          |
| 10    | 10         | Wound swab      | R          | R        | R          | S          |
| 11    | 11         | Wound swab      | R          | I        | I          | S          |
| 12    | 12         | Urine culture   | S          | S        | S          | S          |
| 13    | 13         | Blood culture   | I          | S        | S          | S          |
| 14    | 14         | Blood           | R          | R        | S          | R          |
| 15    | 15         | Sputum          | S          | S        | S          | S          |
| 16    | 16         | Wound           | S          | S        | S          | S          |
| 17    | 17         | Blood           | R          | S        | S          | S          |
| 18    | 18         | Eye             | R          | R        | R          | S          |
| 19    | 19         | Sputum          | I          | S        | S          | S          |
| 20    | 20         | Wound           | R          | R        | R          | R          |
| 21    | 21         | Wound           | I          | R        | R          | R          |
| 22    | 22         | Wound           | I          | S        | S          | S          |
| 23    | 23         | Wound           | S          | S        | I          | S          |
| 24    | 24         | Throat          | I          | I        | I          | S          |
| 25    | 25         | Blood           | R          | S        | I          | S          |
| 26    | 26         | Urine           | R          | I        | I          | S          |
| 27    | 27         | Wound           | I          | S        | S          | S          |
| 28    | 28         | Wound           | I          | S        | S          | S          |
| 29    | 29         | Sputum          | R          | I        | R          | S          |
| 30    | 30         | Pus             | I          | S        | S          | S          |
| 31    | 31         | Blood           | I          | S        | S          | S          |
| 32    | 32         | Wound swab      | I          | S        | S          | S          |
| 33    | 33         | Wound Swab      | I          | S        | S          | S          |
|   |   | Continued |
|---|---|-----------|
|   |   | Sputum culture | I | S | S | S |
| 34 | 34 | Wound swab | R | R | R | R |
| 35 | 35 | Blood | R | R | R | R |
| 36 | 36 | Urine culture | I | S | S | S |
| 37 | 37 | Sputum | I | S | S | S |
| 38 | 38 | Sputum | I | I | I | S |
| 39 | 39 | Sputum | I | S | S | S |
| 40 | 40 | Wound swab | R | I | R | S |
| 41 | 41 | Wound swab | I | S | S | S |
| 42 | 42 | Wound swab | I | S | S | S |
| 43 | 43 | Wound swab | R | I | R | S |
| 44 | 44 | Urine culture | R | R | R | R |
| 45 | 45 | Sputum | R | R | R | R |
| 46 | 46 | Sputum | I | S | S | S |
| 47 | 47 | Wound swab | S | S | S | S |
| 48 | 48 | Blood culture | R | S | S | S |
| 49 | 49 | Wound swab | R | S | S | S |
| 50 | 50 | Blood culture | R | R | R | S |
| 51 | 51 | Urine culture | I | S | S | S |
| 52 | 52 | Urine culture | I | S | S | S |
| 53 | 53 | Urine culture | S | S | S | S |
| 54 | 54 | Contact lense | R | I | I | S |
| 55 | 55 | Wound swab | I | S | S | S |
| 56 | 56 | Urine culture | I | S | S | S |
| 57 | 57 | Sputum | R | I | R | S |
| 58 | 58 | Wound | S | S | S | S |
| 59 | 59 | Sputum | I | S | S | S |
| 60 | 60 | Urine culture | S | S | S | S |
| 61 | 61 | Sputum | I | S | S | S |
| 62 | 62 | Sputum | I | S | S | S |
| 63 | 63 | Sputum | S | S | S | S |
| 64 | 64 | Tip culture | S | S | S | S |
| 65 | 65 | Pus culture | R | S | R | I |
| 66 | 66 | Wound | R | R | R | R |
| 67 | 67 | Wound | R | S | S | R |
| 68 | 68 | Blood | R | R | R | S |
| 69 | 69 | Sputum culture | R | R | R | S |
| 70 | 70 | Blood | R | R | R | I |
|   |   |   |   |   |   |
|---|---|---|---|---|---|
| 71 | 71 | Wound | R | R | R |
| 72 | 72 | Throat swab | R | R | R | S |
| 73 | 73 | Wound | R | R | R | S |
| 74 | 74 | Throat swab | S | S | S | S |
| 75 | 75 | Sputum | R | R | R | R |
| 76 | 76 | Urine | I | S | S | S |
| 77 | 77 | Sputum | R | R | R | R |
| 78 | 78 | Wound | R | R | R | I |
| 79 | 79 | Sputum | R | R | R | R |
| 80 | 80 | Sputum | R | R | R | R |
| 81 | 81 | Blood | S | S | S | S |
| 82 | 82 | Urine | S | S | S | I |
| 83 | 83 | Urine | R | S | S | S |
| 84 | 84 | Urine | R | S | R | R |
| 85 | 85 | Blood | I | S | S | S |
| 86 | 86 | Urine | R | R | R | R |
| 87 | 87 | Throat | R | R | R | I |
| 88 | 88 | Wound | R | R | R | I |
| 89 | 89 | Sputum | R | R | R | R |
| 90 | 90 | Sputum | R | S | R | S |
| 91 | 91 | Urine | R | R | R | R |
| 92 | 92 | Urine | R | R | R | R |
| 93 | 93 | Sputum | R | R | S | R |
| 94 | 94 | Sputum | R | R | R | S |
| 95 | 95 | Eye swab | S | R | S | R |
| 96 | 96 | Sputum | R | R | R | R |
| 97 | 97 | Wound | R | R | R | R |
| 98 | 98 | Sputum | S | R | I | S |
| 99 | 99 | Urine | R | R | S | R |
| 100 | 100 | Sputum | S | R | R | R |
| 101 | 101 | Sputum | R | R | R | S |
| 102 | 102 | Sputum | R | R | R | S |
| 103 | 103 | Urine | I | S | S | S |
| 104 | 104 | Wound | R | R | R | S |
| 105 | 105 | Sputum | I | I | I | R |
| 106 | 106 | Eye | I | R | R | S |
| 107 | 107 | Wound | R | R | R | R |
|   |   |   |   |   |   |
|---|---|---|---|---|---|
| 108| 108| Sputum | S | S | S |
| 109| 109| Sputum | R | R | I |
| 110| 110| Sputum | R | R | R |
| 111| 111| Wound | I | I | R |
| 112| 112| Sputum | R | R | R |
| 113| 113| Sputum | I | S | S |
| 114| 114| Wound | R | I | I |
| 115| 115| Eye | S | R | R |
| 116| 116| Urine | R | I | S |
| 117| 117| Corneal pus | S | S | R |
| 118| 118| Stool | I | S | S |
| 119| 119| Wound | R | R | R |
| 120| 120| Sputum | R | R | R |
| 121| 121| Sputum | R | R | R |
| 122| 122| Sputum | R | R | R |
| 123| 123| Wound | I | S | S |
| 124| 124| Sputum | I | S | S |
| 125| 125| Sputum | S | S | S |
| 126| 126| Urine | R | I | R |
| 127| 127| Sputum | I | I | I |
| 128| 128| Conjuctive | I | S | S |
| 129| 129| Pus | I | I | I |
| 130| 130| Urine | S | S | S |
| 131| 131| Throat | S | S | S |
| 132| 132| Throat | R | R | R |
| 133| 133| Wound | I | I | I |
| 134| 134| Wound | R | R | R |
| 135| 135| Sputum | R | R | R |
| 136| 136| Pus | R | R | R |
| 137| 137| Wound | I | S | S |
| 138| 138| Wound | I | S | S |
| 139| 139| Wound | R | R | R |
| 140| 140| Sputum | S | S | S |
| 141| 141| Eye | R | R | R |
| 142| 142| Throat | I | I | I |
| 143| 143| Sputum | R | R | R |
| 144| 144| Sputum | S | R | I |
Continued

|    |    |    |    |    |
|----|----|----|----|----|
| 145| 145| Wound| R  | I  | R  | R  |
| 146| 146| Wound| S  | S  | S  | S  |
| 147| 147| Sputum| R  | I  | I  | R  |
| 148| 148| Throat| S  | S  | I  | S  |
| 149| 149| Throat| I  | I  | R  | S  |
| 150| 150| Wound| R  | R  | R  | S  |
| 151| 151| Pus   | R  | R  | R  | S  |
| 152| 152| Urine | R  | R  | R  | R  |
| 153| 153| Urine | R  | R  | R  | S  |
| 154| 154| Wound | I  | S  | S  | S  |
| 155| 155| Sputum| R  | R  | I  | R  |
| 156| 156| Sputum| I  | I  | I  | S  |
| 157| 157| Sputum| R  | R  | I  | R  |
| 158| 158| Sputum| R  | R  | R  | R  |
| 159| 159| Wound | I  | S  | S  | S  |
| 160| 160| Wound | R  | I  | R  | R  |
| 161| 161| Wound | R  | R  | R  | R  |
| 162| 162| Pus   | R  | R  | R  | S  |
| 163| 163| Throat| R  | R  | R  | R  |
| 164| 164| Wound | R  | R  | R  | S  |
| 165| 165| Sputum| R  | R  | R  | R  |
| 166| 166| Blood | R  | R  | R  | S  |
| 167| 167| Stool | I  | I  | R  | S  |
| 168| 168| Blood | I  | I  | I  | R  |
| 169| 169| Urine | S  | I  | R  | R  |
| 170| 170| Sputum| S  | S  | S  | S  |
| 171| 171| Sputum| R  | R  | R  | R  |
| 172| 172| Sputum| R  | R  | R  | R  |
| 173| 173| Wound | R  | R  | R  | R  |

Legends: R—Resistant, SI—Sensitive, I—Intermediate.

22.5% of the isolated were resistant to all the anti Pseudomonal antibiotics (Piper- cillin, Cefepime, Ceftazidime & Gentamycin) while 17.3% isolates were resis- tant to three commonly used anti Pseudomonal drugs such as Pipercillin, cefep- ime, Ceftazidime. In addition it was also analyzed that the highest percentage of multi drug resistant P. aeruginosa strains where associated with wound (20.2%) and respiratory tract infections (24%). while 5.7% of urine and 4% of blood isolates showed multi drug resistance. Our findings differ with the find- ings conducted in Riyadh Saud Arabia in which it was documented that most of
the MDR *P. aeruginosa* strains were associated with skin and wound swabs (47.3%) in 2004 & 2005; urine sample where the second most common samples to obtain MDR *P. aeruginosa* strains (26.3% & 33.3%) while respiratory specimens showed third common association with MDR *P. aeruginosa* (21% & 25%) in the respective studied years [21]. In our study the respiratory specimens (sputum and throat swabs) showed the highest percentage of association (24%) of MDR *P. aeruginosa* strains while wound swabs where the second most common specimens that showed association with MDR *P. aeruginosa* strains. In recent years Colistin is been used extensively to treat multidrug resistance *P. aeruginosa* infections. In the present study firstly we evaluated the effect of Colistin on twenty nine clinical isolates of multi drug resistance *Pseudomonas aeruginosa* collected from different hospitals of Jazan region of Saudi Arabia. To our surprise all the 29 clinical isolates showed Colistin resistance which is in contrary to results stated in study carried out in King Khalid University Hospital, Riyadh, Saudi Arabia (2012). In this study the researchers stated that 93.9% *P. aeruginosa* strains were susceptible to Colistin [22]. Colistin resistance is due to acquisition of
Table 2. Inhibition zones for Colistin susceptibility test (mm).

| S. No. | Sample No. | Sample type     | Antibiotic sensitivity of Colistin |
|--------|------------|-----------------|-----------------------------------|
|        |            | Zone in mm      | R/S                               |
| 1      | 1          | Wound           | 4                                 |
| 2      | 2          | Wound           | 3                                 |
| 3      | 3          | Sputum          | 5                                 |
| 4      | 4          | Wound           | 4                                 |
| 5      | 5          | Blood           | 5                                 |
| 6      | 6          | Sputum          | 4                                 |
| 7      | 7          | Throat swab     | 4                                 |
| 8      | 8          | Throat swab     | 5                                 |
| 9      | 9          | Wound           | 4                                 |
| 10     | 10         | Wound           | 5                                 |
| 11     | 11         | Urine           | 4                                 |
| 12     | 12         | Blood           | 4                                 |
| 13     | 13         | Blood           | 4                                 |
| 14     | 14         | Sputum          | 2                                 |
| 15     | 15         | Wound           | 4                                 |
| 16     | 16         | Sputum          | 4                                 |
| 17     | 17         | Eye             | 4                                 |
| 18     | 18         | Sputum          | 5                                 |
| 19     | 19         | Wound           | 4                                 |
| 20     | 20         | Wound           | 5                                 |
| 21     | 21         | Wound           | 4                                 |
| 22     | 22         | Wound           | 5                                 |
| 23     | 23         | Throat swab     | 3                                 |
| 24     | 24         | Blood           | 5                                 |
| 25     | 25         | Urine           | 4                                 |
| 26     | 26         | Wound           | 4                                 |
| 27     | 27         | Wound           | 4.5                               |
| 28     | 28         | Sputum          | 5                                 |
| 29     | 29         | Sputum          | 5                                 |

mcr-1 gene in plasmid which was described by a study in china [23]. However E. coli strains harboring plasmids carrying mcr-1 gene have been reported from many parts of the world. For example in recent study in conducted in UAE found plasmids carrying mcr-1 gene in four strains of E. coli collected from Arabian peninsula [24]. Similarly in a study on hajj pilgrims demonstrated the presence of mcr-1 gene in 10 isolates of E. coli [25]. In another study on
Table 3. Fractional inhibitory concentration index (FICI) of twenty nine MDR Pseudomonas aeruginosa strains.

| Sample number | MIC for Colistin | MIC for Streptomycin | MIC FOR CS Colistin in combo | Strep in combo | FICI |
|---------------|------------------|----------------------|-----------------------------|---------------|------|
| 1             | 62.5             | 62.5                 | 62.5                        | 31.25         | 31.25| 1   |
| 2             | 31.25            | 15.625               | 62.5                        | 31.25         | 31.25| 3   |
| 3             | 31.25            | 62.5                 | 125                         | 62.5          | 62.5 | 3   |
| 4             | 62.5             | 62.5                 | 15.625                      | 7.81          | 7.81 | 0.24|
| 5             | 500              | 250                  | 125                         | 62.5          | 62.5 | 0.75|
| 6             | 15.625           | 31.25                | 15.625                      | 7.81          | 7.81 | 0.73|
| 7             | 15.625           | 250                  | 7.81                        | 3.9           | 3.9  | 0.04|
| 8             | 125              | 500                  | 7.81                        | 3.9           | 3.9  | 0.03|
| 9             | 7.81             | 7.81                 | 500                         | 250           | 250  | 32.5|
| 10            | 7.81             | 7.81                 | 7.81                        | 3.9           | 3.9  | 0.98|
| 11            | 250              | 250                  | 500                         | 250           | 250  | 2   |
| 12            | 31.25            | 31.25                | 15.625                      | 7.81          | 7.81 | 0.48|
| 13            | 15.625           | 7.81                 | 7.81                        | 3.9           | 3.9  | 0.73|
| 14            | 31.25            | 250                  | 31.25                       | 15.625        | 15.625| 0.31|
| 15            | 31.25            | 31.25                | 31.25                       | 15.625        | 15.625| 1   |
| 16            | 125              | 250                  | 7.81                        | 3.9           | 3.9  | 0.04|
| 17            | 125              | 250                  | 31.25                       | 15.625        | 15.625| 0.18|
| 18            | 250              | 250                  | 7.81                        | 3.9           | 3.9  | 0.03|
| 19            | 1000             | 31.25                | 7.81                        | 3.9           | 3.9  | 0.12|
| 20            | 15.625           | 7.81                 | 7.81                        | 3.9           | 3.9  | 0.73|
| 21            | 15.625           | 500                  | 7.81                        | 3.9           | 3.9  | 0.5 |
| 22            | 31.25            | 31.25                | 7.81                        | 3.9           | 3.9  | 0.48|
| 23            | 15.625           | 15.625               | 7.81                        | 3.9           | 3.9  | 0.48|
| 24            | 15.625           | 15.625               | 7.81                        | 3.9           | 3.9  | 0.48|
| 25            | 15.625           | 31.25                | 7.81                        | 3.9           | 3.9  | 0.37|
| 26            | 125              | 250                  | 62.5                        | 31.25         | 31.25| 0.37|
| 27            | 62.5             | 62.5                 | 31.25                       | 15.625        | 15.625| 0.5 |
| 28            | 15.625           | 7.81                 | 7.81                        | 3.9           | 3.9  | 0.74|
| 29            | 62.5             | 7.81                 | 31.25                       | 15.625        | 15.625| 2.25|

Legends: MIC—minimum inhibitory concentration, CS—Colistin, FICI—fractional inhibitory concentration index.

emergence of antimicrobial resistance in Saudi Arabia stated that there may be more isolates of mcr-1 positive E. coli isolates in the country and it is most likely to have dissemination of mcr-1 conjugated plasmid to other species [26]. Therefore in our study we suggest that the Colistin resistance in the tested isolates may
be attributed to the acquisition of mcr-1 gene in *Pseudomonas aeruginosa* form mcr-1 positive *E. coli* strains. However a molecular investigation is required to prove it.

In the present study the synergistic action of two drugs *i.e.* Colistin and streptomycin was determined. It was found that the two drugs when combined showed synergistic killing of 55.1% of tested strains (*FICI* range 0.03 - 0.50). A number of studies have demonstrated the synergistic killing of *P. aeruginosa* strains by using different combinations of drugs for example in a study on synergistic activity of streptomycin and cefadroxil was observed to be synergistic against 39 strains of *P. aeruginosa* (*FICI* = 0.16 – 0.50) [19]. In another study Colistin when combined with antibiotics like trimethoprim, and other combined drugs like trimethoprim-sulfamethoxazole, or vancomycin showed synergistic killing of 12 tested *P. aeruginosa* isolates which included both multidrug resistant and Colistin resistant strains [27]. Similarly a study evaluated the synergistic activity of Colistin with dorpenem that showed substantial synergistic killing of Colistin-heteroresistant reference strain (ATCC 27853) and a Colistin-resistant MDR clinical isolate (19147 n/m) at a low inoculum of ~10^6 [13]. The studies pertaining to synergistic activity of Colistin with other drugs on Colistin resistant *P. aeruginosa* seems to suggest that Colistin resistance may encourage synergistic killing of Colistin resistant strains when combination includes Colistin and other antibiotics. However further research is required to understand the actual mechanism. Nevertheless *in vivo* trials also have showed that aerosolized Colistin is effective as supplemental therapy in patients with nosocomial pneumonia or trachea bronchitis resulting from MDR *P. aeruginosa* [8]. Hence Colistin may be included in the combination therapies to treat the infections caused by Colistin resistant MDR *P. aeruginosa*.

Our study is first of its kind to evaluate Colistin with streptomycin effect on MDR *Pseudomonas aeruginosa*. Streptomycin belongs to aminoglycosides and is used as anti tuberculous drugs. It inhibits protein synthesis in bacterial cell. However researchers have demonstrated the bactericidal activity of streptomycin against *Pseudomonas aeruginosa* [19] [28] but recent studies has demonstrated the developing streptomycin resistance in *Pseudomonas aeruginosa* [29] [30]. Therefore our study suggest that Colistin and streptomycin combined therapy may prove to be effective in treating *Pseudomonas aeruginosa* infections caused by MDR strains and as well as MDR strains that are resistant to Colistin and streptomycin antibiotics. Our study is also the first study report the antagonism between streptomycin and Colistin (*FICI* = 32.5). Therefore we recommend that it’s very essential to choose the antibiotic combinations carefully and the combination should be evaluated before administration.

### 5. Conclusion and Recommendations

Based on data obtained we conclude that multi drug resistance Pseudomonal infections are on rise in this region (55.5%). In addition most of the MDR strains...
(100% in our study) are Colistin resistant. Therefore care should be taken before reintroducing the use of Colistin to treat MDR Pseudomonal infections in this region. As well as antibiotic-resistant patterns should be considered before following the universal antibiotic guidelines. It is also recommended to use Colistin only after performing Colistin susceptibility test for the MDR isolates. Nevertheless an alternate solution of using combined therapy is also recommended to overcome the infections caused by this superbug. In addition use of Colistin and streptomycin combinations may provide a better therapeutic option to combat the MDR and Colistin resistant Pseudomonal infections but requires in vivo studies.

Authors’ Contribution
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

Funding
None.

Data Availability
All datasets generated or analyzed during this study are included in the manuscript and/or the Supplementary Files.

Ethics Statement
This article does not contain any studies with human participants or animals performed by any of the authors.

Acknowledgements
The authors acknowledge Prince Mohammed bin Nasser hospital for its support during this work.

Conflicts of Interest
The authors declare that there are no conflicts of interest.

References
[1] Gellatly, S.L. and Hancock, R.E. (2013) Pseudomonas Aeruginosa: New Insights into Pathogenesis and Host Defenses. Pathogens and Disease, 67, 159-173. https://doi.org/10.1111/2049-632X.12033
[2] Livermore, D.M. (2002) Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas Aeruginosa: Our Worst Nightmare? Clinical Infectious Diseases, 34, 634-640. https://doi.org/10.1086/338782
[3] Mesaros, N., Nordmann, P., Plesiat, P., Roussel-Delvallez, M., Van Eldere, J., Glupczynski, Y., et al. (2007) Pseudomonas aeruginosa: Resistance and Therapeutic Options at the Turn of the New Millennium. Clinical Microbiology and Infection, 13, 560-578. https://doi.org/10.1111/j.1469-0691.2007.01681.x
[4] Aloush, V., Navon-Venezia, S., Seigman-Igra, Y., Cabili, S. and Carmeli, Y. (2006) Multidrug-Resistant *Pseudomonas aeruginosa*: Risk Factors and Clinical Impact. *Antimicrobial Agents and Chemotherapy*, 50, 43-48. https://doi.org/10.1128/AAC.50.1.43-48.2006

[5] Lambert, P. (2002) Mechanisms of Antibiotic Resistance in *Pseudomonas aeruginosa*. *Journal of the Royal Society of Medicine*, 95, 22.

[6] Morita, Y., Tomida, J. and Kawamura, Y. (2014) Responses of *Pseudomonas aeruginosa* to Antimicrobials. *Frontiers in Microbiology*, 4, 422. https://doi.org/10.3389/fmicb.2013.00422

[7] Aly, M. and Balkhy, H.H. (2012) The Prevalence of Antimicrobial Resistance in Clinical Isolates from Gulf Corporation Council Countries. *Antimicrobial Resistance and Infection Control*, 1, 26. https://doi.org/10.1186/2047-2994-1-26

[8] Hamer, D.H. (2000) Treatment of Nosocomial Pneumonia and Tracheobronchitis Caused by Multidrug-Resistant *Pseudomonas aeruginosa* with Aerosolized Colistin. *American Journal of Respiratory and Critical Care Medicine*, 162, 328-330. https://doi.org/10.1164/ajrccm.162.1.9910071

[9] Hachem, R.Y., Chemaly, R.F., Ahmar, C.A., Jiang, Y., Boktour, M.R., Rjaili, G.A., et al. (2007) Colistin Is Effective in Treatment of Infections Caused by Multidrug-Resistant *Pseudomonas aeruginosa* in Cancer Patients. *Antimicrobial Agents and Chemotherapy*, 51, 1905-1911. https://doi.org/10.1128/AAC.01015-06

[10] Levin, A.S., Barone, A.A., Penco, J., Santos, M.V., Marinho, I.S., Arruda, E.A., et al. (1999) Intravenous Colistin as Therapy for Nosocomial Infections Caused by Multidrug-Resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. *Clinical Infectious Diseases*, 28, 1008-1011. https://doi.org/10.1086/514732

[11] Goli, H.R., Nahaei, M.R., Rezaee, M.A., Hasani, A., Kafil, H.S. and Aghazadeh, M. (2016) Emergence of Colistin Resistant *Pseudomonas aeruginosa* at Tabriz Hospitals, Iran. *Iranian Journal of Microbiology*, 8, 62.

[12] Denton, M., Kerr, K., Mooney, L., Keer, V., Raigopal, A., Brownlee, K., et al. (2002) Transmission of Colistin-Resistant *Pseudomonas aeruginosa* between Patients Attending a Pediatric Cystic Fibrosis Center. *Pediatric Pulmonology*, 34, 257-261. https://doi.org/10.1002/ppul.10166

[13] Bergen, P.J., Tsuji, B.T., Bulitta, J.B., Forrest, A., Jacob, J., Sidjabat, H.E., et al. (2011) Synergistic Killing of Multidrug-Resistant *Pseudomonas aeruginosa* at Multiple Inocula by Colistin Combined with Doripenem in an *in Vitro* Pharmacokinetic/Pharmacodynamic Model. *Antimicrobial Agents and Chemotherapy*, 55, 5685-5695. https://doi.org/10.1128/AAC.05298-11

[14] Cursino, L., Chartone-Souza, E. and Nascimento, A.M.A. (2005) Synergic Interaction between Ascorbic Acid and Antibiotics against *Pseudomonas aeruginosa*. *Brazilian Archives of Biology and Technology*, 48, 379-384. https://doi.org/10.1590/S1516-89132005000300007

[15] Gaby, W. and Hadley, C. (1957) Practical Laboratory Test for the Identification of *Pseudomonas aeruginosa*. *Journal of Bacteriology*, 74, 356.

[16] Cavaleri, J., Rankin, D., Harbeck, J., Sautter, L., McCarter, S., Sharp, S., et al. (2005) Manual of Antimicrobial Susceptibility Testing. American Society for Microbiology, Seattle.

[17] Andrews, J.M. (2001) Determination of Minimum Inhibitory Concentrations. *Journal of Antimicrobial Chemotherapy*, 48, 5-16. https://doi.org/10.1093/jac/48.suppl_1.5

[18] Cai, Y., Wang, R., Pei, F. and Liang, B.-B. (2007) Antibacterial Activity of Allicin
Alone and in Combination with β-Lactams against *Staphylococcus* spp. and *Pseudomonas aeruginosa*. *The Journal of Antibiotics*, **60**, 335. https://doi.org/10.4236/aim.2019.910054

[19] Ahmed, Z., Khan, S.S. and Khan, M. (2013) *In Vitro* Trials of Some Antimicrobial Combinations against *Staphylococcus aureus* and *Pseudomonas aeruginosa*. *Saudi Journal of Biological Sciences*, **20**, 79-83. https://doi.org/10.1016/j.sjbs.2012.10.005

[20] Memish, Z.A., Shibil, A.M., Kambal, A.M., Ohaly, Y.A., Ishaq, A. and Livermore, D.M. (2012) Antimicrobial Resistance among Non-Fermenting Gram-Negative Bacteria in Saudi Arabia. *Journal of Antimicrobial Chemotherapy*, **67**, 1701-1705. https://doi.org/10.1093/jac/dks091

[21] Babay, H.A. (2007) Antimicrobial Resistance among Clinical Isolates of *Pseudomonas aeruginosa* from Patients in a Teaching Hospital, Riyadh, Saudi Arabia, 2001-2005. *Japanese Journal of Infectious Diseases*, **60**, 123-125.

[22] Somily, A.M., Absar, M.M., Arshad, M.Z., Al Aska, A.I., Shakoor, Z.A., Fatani, A.J., et al. (2012) Antimicrobial Susceptibility Patterns of Multidrug-Resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii* against Carbapenems, Colistin, and Tigecycline. *Saudi Medical Journal*, **33**, 750-755.

[23] Liu, Y.-Y., Wang, Y., Walsh, T.R., Yi, L.-X., Zhang, R., Spencer, J., et al. (2016) Emergence of Plasmid-Mediated Colistin Resistance Mechanism MCR-1 in Animals and Human Beings in China: A Microbiological and Molecular Biological Study. *The Lancet Infectious Diseases*, **16**, 161-168. https://doi.org/10.1016/S1473-3099(15)00424-7

[24] Sonnevend, Á., Ghazawi, A., Alqahtani, M., Shibil, A., Jamal, W., Hashmey, R., et al. (2016) Plasmid-Mediated Colistin Resistance in *Escherichia coli* from the Arabian Peninsula. *International Journal of Infectious Diseases*, **50**, 85-90. https://doi.org/10.1016/j.ijid.2016.07.007

[25] Leangapichart, T., Gautret, P., Brouqui, P., Mimish, Z., Raoult, D. and Rolain, J.-M. (2016) Acquisition of mcr-1 Plasmid-Mediated Colistin Resistance in *Escherichia coli* and *Klebsiella pneumoniae* during Hajj 2013 and 2014. *Antimicrobial Agents and Chemotherapy*, **60**, 6998-6999. https://doi.org/10.1128/AAC.01486-16

[26] Zowawi, H.M. (2016) Antimicrobial Resistance in Saudi Arabia: An Urgent Call for an Immediate Action. *Saudi Medical Journal*, **37**, 935. https://doi.org/10.15537/smj.2016.9.16139

[27] Vidaillac, C., Benichou, L. and Duval, R.E. (2012) *In Vitro* Synergy of Colistin Combinations against Colistin-Resistant *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae* Isolates. *Antimicrobial Agents and Chemotherapy*, **56**, 4856-4861. https://doi.org/10.1128/AAC.05996-11

[28] Hancock, R., Raffle, V.J. and Nicas, T.I. (1981) Involvement of the Outer Membrane in Gentamicin and Streptomycin Uptake and Killing in *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy*, **19**, 777-785. https://doi.org/10.1128/AAC.19.5.777

[29] Poole, K. (2005) Aminoglycoside Resistance in *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy*, **49**, 479-487. https://doi.org/10.1128/AAC.49.2.479-487.2005

[30] Cervantes-Vega, C., Chávez, J. and Rodriguez, M. (1986) Antibiotic Susceptibility of Clinical Isolates of *Pseudomonas aeruginosa*. *Antonie Van Leeuwenhoek*, **52**, 319-324. https://doi.org/10.1007/BF00428643